Interface Biologics Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
7
- Latest Deal Type
-
M&A
Interface Biologics General Information
Description
Developer of biomedical polymer technology designed to improve the efficacy of medical devices and targeted delivery of drugs. The company's technology uses surface modification additives that are used in FDA-cleared medical devices and are clinically proven to reduce infection and thrombus-related complications and are applicable across a range of drug classes and medical specialties with a focus on ophthalmology, enabling clinicians to improve the safety and effectiveness of medical devices.
Contact Information
Website
www.interfacebiologics.comCorporate Office
- MaRS Centre, South Tower, 101 College Street
- Suite 300
- Toronto, Ontario M5G 1L7
- Canada
Corporate Office
- MaRS Centre, South Tower, 101 College Street
- Suite 300
- Toronto, Ontario M5G 1L7
- Canada
Interface Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 03-Sep-2019 | Completed | Generating Revenue | |||
| 8. Later Stage VC | Completed | Generating Revenue | ||||
| 7. Later Stage VC (Series B) | 13-Jan-2015 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 06-Dec-2011 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 10-Jan-2011 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 11-Dec-2008 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 30-Sep-2004 | Completed | Generating Revenue | |||
| 2. Seed Round | 28-Jan-2002 | $1M | $1M | Completed | Generating Revenue | |
| 1. University Spin-Out | 01-Jan-2001 | Completed | Startup |
Interface Biologics Patents
Interface Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3796948-A1 | Compositions and methods for delivering drugs to a vessel wall | Inactive | 22-May-2018 | ||
| EP-3796948-A4 | Compositions and methods for delivering drugs to a vessel wall | Inactive | 22-May-2018 | ||
| US-11318232-B2 | Compositions and methods for delivering drugs to a vessel wall | Inactive | 22-May-2018 | ||
| US-20200188560-A1 | Compositions and methods for delivering drugs to a vessel wall | Active | 22-May-2018 | ||
| US-20220362440-A1 | Compositions and methods for delivering drugs to a vessel wall | Inactive | 22-May-2018 | A61L29/085 |
Interface Biologics Signals
Interface Biologics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BDC Capital | Growth/Expansion | Minority | ||
| Covington Capital Corporation | Venture Capital | Minority | ||
| Genesys Capital | Venture Capital | Minority | ||
| MaRS Investment Accelerator Fund | Venture Capital | Minority | ||
| Ontario Centre of Innovation | Not-For-Profit Venture Capital | Minority |
Interface Biologics FAQs
-
When was Interface Biologics founded?
Interface Biologics was founded in 2001.
-
Where is Interface Biologics headquartered?
Interface Biologics is headquartered in Toronto, Canada.
-
What is the size of Interface Biologics?
Interface Biologics has 7 total employees.
-
What industry is Interface Biologics in?
Interface Biologics’s primary industry is Drug Delivery.
-
Is Interface Biologics a private or public company?
Interface Biologics is a Private company.
-
What is Interface Biologics’s current revenue?
The current revenue for Interface Biologics is .
-
How much funding has Interface Biologics raised over time?
Interface Biologics has raised $31.5M.
-
Who are Interface Biologics’s investors?
BDC Capital, Covington Capital Corporation, Genesys Capital, MaRS Investment Accelerator Fund, and Ontario Centre of Innovation are 5 of 8 investors who have invested in Interface Biologics.
-
When was Interface Biologics acquired?
Interface Biologics was acquired on 03-Sep-2019.
-
Who acquired Interface Biologics?
Interface Biologics was acquired by Evonik Industries.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process